CAMP
NASDAQCAMP4 Therapeutics Corporation
IPO2024
Website
News25/Ratings12
News · 26 weeks45+43%
2025-10-262026-04-19
Mix1990d
- SEC Filings6(32%)
- Insider6(32%)
- Other5(26%)
- Leadership1(5%)
- Analyst1(5%)
Latest news
25 items- SECSEC Form DEFA14A filed by CAMP4 Therapeutics CorporationDEFA14A - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form DEF 14A filed by CAMP4 Therapeutics CorporationDEF 14A - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on April 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry
- ANALYSTRodman & Renshaw initiated coverage on CAMP4 Therapeutics with a new price targetRodman & Renshaw initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $7.00
- INSIDERSEC Form 4 filed by Tardiff Daniel4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Maricich Yuri4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Gold Kelly4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Mandel-Brehm Josh4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Maclean Michael F4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 3 filed by new insider Maclean Michael F3 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Leadership Update8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Appoints Michael MacLean to its Board of DirectorsCAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors. "Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4's Board," said Josh Mandel-Brehm, Pr
- PRCAMP4 to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare ConferenceFormat:Fireside ChatDate and Time:March 9, 2026, 8:40 a.m. ETLocation:Miami, FLWebcast Link:Click Here Stifel CNS ForumFormat:Corporate PresentationDate and Time:March 17, 2026, 10:00 a.m.
- SECSEC Form S-8 filed by CAMP4 Therapeutics CorporationS-8 - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form 10-K filed by CAMP4 Therapeutics Corporation10-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Reports Full Year 2025 Financial Results and Corporate HighlightsGLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common stock of $30 million in gross proceeds, extending cash runway into 2028 CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDA
- PRCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on February 16, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CAMP4 Therapeutics CorporationSCHEDULE 13G/A - Camp4 Therapeutics Corp (0001736730) (Subject)
- PRCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the C
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form SCHEDULE 13G filed by CAMP4 Therapeutics CorporationSCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
- PRCAMP4 to Present at the 44th Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST. The event will be webcast and can be accessed on the investor relations page of CAMP4's website at
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Tardiff Daniel4 - Camp4 Therapeutics Corp (0001736730) (Issuer)